OCF Yield % is calculated as Cash Flow from Operations divided by Market Capitalization. It is a financial solvency ratio that compares the operating cash flow a company is expected to earn against its market value.
Japan Tissue Engineering Co OCF Yield % Explanation
Similar to Earnings Yield %, OCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high operating cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.
Japan Tissue Engineering Co OCF Yield % Related Terms
Japan Tissue Engineering Co OCF Yield % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TSE:7774 vs VRTX, REGN, ALNY: OCF Yield % Comparison
For the Biotechnology subindustry, Japan Tissue Engineering Co's OCF Yield %, along with its competitors' market caps and OCF Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Japan Tissue Engineering Co OCF Yield % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Japan Tissue Engineering Co's OCF Yield % distribution charts can be found below:
* The bar in red indicates where Japan Tissue Engineering Co's OCF Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Japan Tissue Engineering Co (TSE:7774) has a OCF Yield % of -1.96 as of Jul. 09, 2026. OCF Yield is calculated as Cash Flow from Operations divided by Market Capitalization. View historical data on Japan Tissue Engineering Co and its competitors. According to the industry distribution chart, Japan Tissue Engineering Co ranks #417 out of 1408 companies in the Biotechnology industry, placing it in the top 29.6%.
Is Japan Tissue Engineering Co's OCF Yield % too high?
Japan Tissue Engineering Co's current OCF Yield % is -1.96. Based on the distribution chart, Japan Tissue Engineering Co ranks #417 out of 1408 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Japan Tissue Engineering Co has a GF Score™ of 60/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Japan Tissue Engineering Co's OCF Yield % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Japan Tissue Engineering Co ranks #417 out of 1408 companies for OCF Yield %. This puts Japan Tissue Engineering Co in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Yield % for a Biotechnology company?
A good OCF Yield % depends on the Biotechnology industry context. However, OCF Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Yield % mean?
A high OCF Yield % can signal that a stock is expensive relative to its fundamentals. OCF Yield is calculated as Cash Flow from Operations divided by Market Capitalization. View historical data on Japan Tissue Engineering Co and its competitors. Japan Tissue Engineering Co's current OCF Yield % is -1.96. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Japan Tissue Engineering Co stock overvalued right now?
Based on GuruFocus' analysis, Japan Tissue Engineering Co (TSE:7774) is currently considered Modestly Overvalued. The stock's GF Value™ is 円517.18, compared to a current price of 円630.00 — trading 21.8% above its estimated fair value. The current OCF Yield % is -1.96. Japan Tissue Engineering Co's overall GF Score™ is 60/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Yield % calculated?
OCF Yield % is calculated from a company's financial statements. For Japan Tissue Engineering Co (TSE:7774), the current OCF Yield % is -1.96 as of Jul. 09, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Japan Tissue Engineering Co (TSE:7774) Overvalued in 2026?
Based on GuruFocus' analysis, Japan Tissue Engineering Co stock appears to be overvalued.
The current stock price of 円630.00 is trading 21.8% above its estimated GF Value™ of 円517.18.
GuruFocus considers Japan Tissue Engineering Co to be Modestly Overvalued.
Key valuation signals for TSE:7774:
OCF Yield %: -1.96
GF Value™: 円517.18 vs. price of 円630.00 (21.8% above fair value)
No single metric tells the full story. See the TSE:7774 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Japan Tissue Engineering Co Ltd is a bio-venture enterprise. It is engaged in the development, manufacture, and sale of tissue-engineered medical products and related products. It operates through the Regenerative Medicine, and Research and Development support business segments. The main business goal is to use autologous culturing techniques to develop tissue-engineered medical products and then to manufacture and sell these same tissue-engineered products to medical institutions for medical treatment. The company's tissue-engineered medical products are used in autologous transplant cases, where living cells are taken from the actual patient himself, cultured and then transplanted back to that same patient.
60GF Score
Get the complete analysis for TSE:7774
OCF Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:7774 has been successfully added to your 
